Dr. Faisal Shuaibu, Executive Director of NPHCDA

Nigeria clarifies no plan to stop use of AstraZeneca COVID-19 Vaccine

*There has been no change to current plans or supply ─National Primary Health Care Development Agency

Alexander Davis | ConsumerConnect

In restating the strong effectiveness of the vaccine brand against the disruptive COVID-19 through clinical and human trials, the National Primary Health Care Development Agency (NPHCDA) has announced that it has no plan to stop the use of AstraZeneca- Oxford Vaccine.

The Nigerian health agency in a statement Saturday, April 3 said the country is continuing the process of administering roughly four million doses of the AstraZeneca-Oxford Vaccine, beginning with frontline health workers and vulnerable individuals.

The NPHCDA stated: “There has been no change to current plans or supply.

“A huge number of countries around the world are administering the Oxford/AstraZeneca vaccine, including much of Europe, and the United Kingdom which has administered the most doses of AstraZeneca globally.”

The agency added: “The World Health Organisation, British and European health regulators all continue to advocate for the use of AstraZeneca.

“AstraZeneca’s strong effectiveness against COVID-19 has been demonstrated in clinical and human trials: it has been shown to be 76% effective at preventing COVID-19 and 100% effective at preventing severe disease and hospitalisation.”

Kindly Share This Story